New pathogenic insights into rheumatoid arthritis

Current Opinion in Rheumatology

Volumn 27, Issue 3, 2015, Pages 249-255

  Jutley, Gurpreet ^a   Raza, Karim ^a   Buckley, Christopher D ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Genetics; Inflammation; Rheumatoid arthritis; Synovium

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; HLA ANTIGEN;

AUTOIMMUNITY; ENVIRONMENTAL FACTOR; GENE LOCUS; GENETIC ASSOCIATION; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; STROMA CELL; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS;

EID: 84926298523     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000174     Document Type: Review

References (63)

1. Gerlag DM, Raza K, van Baarsen LG, et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis (RA): Report from the Study Group for Risk Factors for RA. Ann Rheum Dis 2012; 71:638-641.
2. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365:2205-2219.
3. Raza K, Filer A. Predicting the development of RA in patients with early undifferentiated arthritis. Best Pract Res Clin Rheumatol 2009; 23:25-36.
4. Buckley CD, Pilling D, Lord JM, et al. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol 2001; 22:199-204.
5. Buckley CD, Filer A, Haworth O, et al. Defining a role for fibroblasts in the persistence of chronic inflammatory joint disease. Ann Rheum Dis 2004; 63 (Suppl 2):ii92-ii95.
6. Karouzakis E, Gay RE, Gay S, et al. Epigenetic deregulation in rheumatoid arthritis. Adv Exp Med Biol 2011; 711:137-149.
7. de Pablo P, Chapple IL, Buckley CD, et al. Periodontitis in systemic rheumatic diseases. Nat Rev Rheumatol 2009; 5:218-224.
8. Emery P. Treatment of rheumatoid arthritis. Br Med J 2006; 332:152-155.
9. Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007; 370:1861-1874.
10. van der Helm-van Mil AH, Huizinga TW. Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets. Arthritis Res Ther 2008; 10:205.
11. Stahl EA, Raychaudhuri S, Remmers EF, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 2010; 42:508-514.
12. van der Woude D, Houwing-Duistermaat JJ, Toes RE, et al. Quantitative heritability of anticitrullinated protein antibody-positive and anticitrullinated protein antibody-negative rheumatoid arthritis. Arthritis Rheum 2009; 60:916-923.
13. Raychaudhuri S. Recent advances in the genetics of rheumatoid arthritis. Curr Opin Rheumatol 2010; 22:109-118.
14. Barton A, Worthington J. Genetic susceptibility to rheumatoid arthritis: An emerging picture. Arthritis Rheum 2009; 61:1441-1446.
15. Farh KKH, Marson A, Zhu J, et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 2014; 0:1-7.
16. Okada Y, Wu D, Trynka G, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 2014; 506:376-381.
17. Wright GP, Notely CA, Bendle GM, et al. Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc Natl Acad Sci USA 2009; 106:19078-19083.
18. Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF alpha therapy. J Exp Med 2004; 200:277-285.
19. Flores-Borja F, Jury EC, Mauri C, Ehrenstein MR. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci USA 2008; 105:19396-19401.
20. Ito Y, Hashimoto M, Hirota K, et al. Detection of T cell responses to a ubiquitous cellular protein in autoimmune disease. Science 2014; 346:363-368.
21. Erye S, Bowes J, Diogo D, et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet 2012; 44:1336-1340.
22. Okada Y, Terao C, Ikari K, et al. Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population. Nat Genet 2012; 44:511-516.
23. Zheng X, Suzuki M, ZhangM, et al. RNAi-mediated CD40-CD154 interruption promotes tolerance in autoimmune arthritis. Arthritis Res Ther 2010; 12:R13.
24. Garber K. Pfizer's first in class JAK inhibitor pricey for rheumatoid arthritis market. Nat Biotechnol 2013; 31:3-4.
25. O'Shea JJ, Plenge R. JAK and STAT signalling molecules in immuno-regulation and immune-mediated disease. Immunity 2012; 36:542-550.
26. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signalling. J Clin Invest 2011; 121:3375-3383.
27. Bos WH, Ursum J, de Vries N, et al. The role of the shared epitope in arthralgia with anticyclic citrullinated peptide antibodies (anti-CCP), and its effect on anti-CCP levels. Ann Rheum Dis 2008; 67:1347-1350.
28. Hensvold AH, Magnusson PK, Joshua V, et al. Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: An epidemiological investigation in twins. Ann Rheum Dis 2013; 74:375-380.
29. Demoruelle MK, Weisman MH, Simonian PL, et al. Brief report: Airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: Early injury or initiating site of autoimmunity? Arthritis Rheum 2012; 64:1756-1761.
30. Padyukov L, Silva C, Stolt P, et al. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum 2004; 50:3085-3092.
31. Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54:38-46.
32. Kallberg H, Ding B, Padyukov L, et al. Smoking is a major preventable risk factor for rheumatoid arthritis: Estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis 2011; 70:508-511.
33. Scott IC, Seegobin SD, Steer S, et al. Predicting the risk of rheumatoid arthritis and its age of onset through modelling genetic risk variants with smoking. PloS Genet 2013; 9:1-13.
34. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48:2741-2749.
35. van de Stadt LA, van der Horst AR, de Koning MH, et al. The extent of the anticitrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia. Ann Rheum Dis 2011; 70:128-133.
36. Bos WH, Wolbink GJ, Boers M, et al. Arthritis development in patients with arthralgia is strongly associated with anticitrullinated protein antibody status: A prospective cohort study. Ann Rheum Dis 2010; 69:490-494.
37. Young KA, Deane KD, Derber LA, et al. Relatives without rheumatoid arthritis show reactivity to anticitrullinated protein/peptide antibodies that are associated with arthritis-related traits: Studies of the etiology of rheumatoid arthritis. Arthritis Rheum 2013; 65:1995-2004.
38. Kraan MC, Versendaal H, Jonker M, et al. Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum 1998; 41:1481-1488.
39. van de Sande MG, de Hair MJ, van der Leij C, et al. Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann Rheum Dis 2011; 70:772-777.
40. de Hair MJ, van de Sande MG, Ramwadhdoebe TH, et al. Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis. Arthritis Rheumatol 2014; 66:513-522.
41. Gent YY, Voskuyl AE, Kloet RW, et al. Macrophage PET imaging as biomarker for preclinical rheumatoid arthritis. Arthritis Rheum 2012; 64:62-66.
42. van Steenbergen HW, van Nies JA, Huizinga TW, et al. Characterising arthralgia in the preclinical phase of rheumatoid arthritis using MRI. Ann Rheum Dis 2014; doi: 10.1136/annrheumdis-2014-205522. [Epub ahead of print]
43. Ytterberg AJ, Joshua V, Reynisdottir G, et al. Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation. Ann Rheum Dis 2014; doi: 10.1136/annrheumdis-2013-204912. [Epub ahead of print]
44. Catrina AI, Deane KD, Scher JU. Gene, environment, microbiome and mucosal immune tolerance in rheumatoid arthritis. Rheumatology 2014. [Epub ahead of print]
45. Li J, Kuzin I, Moshkani S, et al. Expanded CD23()/CD21(hi) B cells in inflamed lymph nodes are associated with the onset of inflammatory-erosive arthritis in TNF-transgenic mice and are targets of anti-CD20 therapy. J Immunol 2010; 184:6142-6150.
46. Rodriguez-Palmero M, Pelegri C, Ferri MJ, et al. Alterations of lymphocyte populations in lymph nodes but not in spleen during the latency period of adjuvant arthritis. Inflammation 1999; 23:153-165.
47. van Baarsen LG, de Hair MJ, Ramwadhdoebe TH, et al. The cellular composition of lymph nodes in the earliest phase of inflammatory arthritis. Ann Rheum Dis 2013; 72:1420-1424.
48. Stolt P, Bengtsson C, Nordmark B, et al. Quantification of the influence of cigarette smoking on rheumatoid arthritis: Results from a population based case-control study, using incident cases. Ann Rheum Dis 2003; 62:835-841.
49. Reynisdottir G, Karimi R, Joshua V, et al. Structural changes and antibody enrichment in the lungs are early features of anticitrullinated protein antibodypositive rheumatoid arthritis. Arthritis Rheumatol 2014; 66:31-39.
50. de Pablo P, Dietrich T, Chapple IL, et al. The autoantibody repertoire in periodontitis: A role in the induction of autoimmunity to citrullinated proteins in rheumatoid arthritis? Ann Rheum Dis 2014; 73:580-586.
51. Raza K, Breese M, Nightingale P, et al. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol 2005; 32:231-238.
52. van der Helm-van Mil AH, le Cessie S, van Dongen H, et al. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 2007; 56:433-440.
53. van der Helm-van Mil AH, Detert J, le Cessie S, et al. Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum 2008; 58:2241-2247.
54. Brindle JT, Antti H, Holmes E, et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med 2002; 8:1439-1444.
55. Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457:910-914.
56. Kapoor SR, Filer A, Fitzpatrick MA, et al. Metabolic profiling predicts response to antitumor necrosis factor a therapy in patients with rheumatoid arthritis. Arthritis Rheum 2013; 65:1448-1456.
57. Young SP, Kapoor SR, Viant MR, et al. The impact of inflammation on metabolomic profiles in patients with arthritis. Arthritis Rheum 2013; 65:2015-2023.
58. Haworth O, Cernadas M, Yang R, et al. Resolving E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol 2008; 9:873-879.
59. Lawrence T, Willoughby DA, Gilroy DW. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol 2002; 2:787-795.
60. Serhan CN, Brain SD, Buckley CD, et al. Resolution of inflammation: State of the art, definitions and terms. FASEB J 2007; 21:325-332.
61. Serhan CN, Krishnamoorthy S, Recchiuti A, et al. Novel anti-inflammatory proresolving mediators and their receptors. Curr Top Med Chem 2011; 11:629-647.
62. Harre U, Georgess D, Bang H, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 2012; 122:1791-1802.
63. Kleyer A, Finzel S, Rech J, et al. Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis 2014; 73:854-860.